Life Sciences Tools and Services

Tigermed

Hangzhou Topmed to Hold AGM on June 9 to Vote on Special Resolution for A-Share Buyback

JPMorgan Cuts Tigercat Profit Forecasts and Target Price to 39 HKD

Controlling Shareholder Investigated, Tigermed's 1 Billion Buyback Fails to Stop Stock Decline

China Renaissance Global Fund Increases Stake in Tigermed by 719,300 Shares on May 14 for HKD 25.84 Million

Schroders PLC Reduces Stake in Tigermed by 579,300 Shares on May 14

Norges Bank Increases Holding of Tigermed to 813,800 Shares

Hangzhou Therapeutic Biotechnology Proposes Up to 100 Million Yuan Stock Repurchase Plan

CSO 实际控制 persons under investigation for disclosure violations related to shareholding changes

Goldman Sachs Downgrades Taige Pharma's Profit Forecast and Target Price

China Construction Bank Reiterates Buy Rating on Hangzhou Therasky Medical Consulting's H Shares

Thaleon Pharma Reports Q1 2026 Earnings, Net Profit Plummets

BOCI Downgrades Taige Pharma's Target Price and Adjusts Forecasts

CLSA Reiterates Buy Rating on Hangzhou Theradiag Holdings H Shares

Hangzhou Ther Advant 医药 Releases 2025 Annual Report, Sees 20.6% Increase in Net New Contract Values and Acquires Micron

UBS Raises Target Price for TAAFFE PHARM to HKD 59.9 and Maintains Buy Rating

Tigermed released FY2026 Q1 earnings on April 28 Pre-Market (BJT), actual revenue CNY 1.801 B (forecast CNY 1.736 B), actual EPS CNY 0.06 (forecast CNY 0.2633)

Schroders PLC Increased Holdings in Therapix Biosciences to 6.17%

CITIC Securities Maintains 'Buy' Rating on Hangzhou Theragenics, with a Target Price of HKD 56

Tigermed to Release FY2026 Q1 Earnings on April 28 Pre-Market (BJT), Forecast Revenue CNY 1.803 B, EPS CNY 0.2633

Tigermed and Insilico Medicine Sign Strategic Partnership on AI-Driven Drug R&D

03347

300347

TIGERMEDfell 3.19% to HKD33.42, nearing a one-year low, after JPMorgan cut its target price from HKD41 to HKD39. The decline follows an investigation by the China Securities Regulatory Commission and disappointing earnings in Q1 2026, with recurring net profit rising 18% YoY to RMB120 million, below expectations. JPMorgan has lowered its profit forecasts for 2026-2028 by 12% to 14% while maintaining a Neutral rating.

AASTOCKS News

TIGERMED

JPMorgan Chase

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

TIGERMED  Falls 3% by Midday to Near One-Year Low After JPM Cuts TP to HKD39

TIGERMEDannounced plans to repurchase A shares worth between RMB500 million and RMB1 billion within 12 months. The repurchase will be funded through its own or self-raised funds via centralized bidding transactions. The shares will be used for A-share equity incentive schemes, employee share ownership plans, and to reduce registered capital, with a maximum repurchase price of RMB60 per share.

TIGERMED  Plans to Spend Up to RMB1B to Repurchase A Shares

Hangzhou Tigermed Consulting Co., Ltd. has announced a buyback plan for its A shares, aiming to repurchase between RMB500 million and RMB1 billion at a maximum price of RMB60 per share. The buyback will cover approximately 8.33 million to 16.67 million shares, representing 0.97% to 1.94% of total share capital, over a period of up to 12 months. The repurchased shares will be allocated to an equity incentive scheme and for cancellation to reduce registered capital. This move is expected to enhance shareholder value and align employee interests.

Tip Ranks

Hangzhou Tigermed Unveils Up to RMB1 Billion A-Share Buyback Plan

516500

159849

159837

Citi reported that TIGERMEDshares fell by 5.26% due to compliance issues involving its co-founders' failure to disclose equity changes. Despite this, Citi believes the company's fundamentals remain strong and views the share price decline as a buying opportunity. The broker assigned a target price of RMB67 for TIGERMED CONSULTINGand maintained a Buy rating.

ChinaAMC CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Citi: TIGERMED CONSULTING Fundamentals Unaffected; Share Price Weakness Seen as Entry Pt

TIGERMEDopened 6.58% lower at HKD35.52 following news that directors Ye Xiaoping and Cao Xiaochun are under investigation by the China Securities Regulatory Commission for suspected information disclosure violations. The company stated that both will cooperate with the investigation and that normal business operations will not be affected. Short selling reached $8.90M with a ratio of 130.031%.

TIGERMED Opens 6.6% Lower as Directors and Controlling Shareholders Placed Under Investigation

560600

512290

Shanghai-based Immunocan has successfully closed a RMB250 million Series A funding round, led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing investors like Kingray Capital and TigerYeah Capital. The funds will be utilized to enhance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, develop an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan specializes in antibody discovery using gene-editing technologies and collaborates with various pharmaceutical companies globally.

TechNode

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Guotai CSI Bio-medicine ETF

Tianhong CNI BIOMEDICINE ETF

Penghua SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Ping An CSI Medicine and Medical Device Innovation ETF

First Trust NYSE Arca Biotech Index Fd

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Antibody discovery platform Immunocan closes RMB250 million Series A

Bank of China has reaffirmed its Buy rating for Hangzhou Tigermed Consulting Co., Ltd. Class H, setting a price target of HK$48.00. The overall analyst consensus for the company is a Strong Buy, with an average price target of €6.01.

BANK OF CHINA

Bank Of China

BOC HONG KONG

Bank of China

Bank of China Sticks to Its Buy Rating for Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1)

BOCI has lowered its target price for TIGERMEDfrom HKD51 to HKD48, citing ongoing pressure on profitability despite a 15% YoY revenue growth to RMB1.8 billion in Q1. The broker adjusted its net profit forecasts for 2026-2028 down by 6% to 8%, while free cash flow estimates were also reduced. The report highlights that growth is driven more by project volume than pricing, leading to a decline in gross margin. Despite these challenges, BOCI maintains a Buy rating due to solid cash flow and investment income potential.

BOCI Cuts TIGERMED  TP to HKD48; Profitability Continues to Face Pressure

Hangzhou Tigermed Consulting Co., Ltd. (HK:3347) has announced a final cash dividend of RMB 1.26 per 10 shares for the year ending December 31, 2025, pending shareholder approval on June 2, 2026. The dividend will be paid in HKD on July 31, 2026, with details on the exchange rate to follow. The company clarified withholding tax rates: 10% for non-resident investors and 20% for mainland individual investors. This update aims to enhance transparency regarding post-tax returns and aligns with Chinese tax regulations and Hong Kong disclosure standards. The stock currently has a Buy rating with a target price of HK$55.00.

Hangzhou Tigermed Updates 2025 Final Dividend Terms and Tax Treatment

TIGERMEDreported a 70.4% decline in net profit for Q1, amounting to RMB49.0431 million, despite a 15.2% increase in revenue to RMB1.801 billion year-on-year. The earnings per share (EPS) stood at RMB0.06. The stock saw a rise of 3.774%, with short selling at $15.99 million and a ratio of 14.331%.

TIGERMED 1Q NP RMB49.0431M, Down 70.4%

Tigermed(300347.SZ)

TIGERMED Falls 3% by Midday to Near One-Year Low After JPM Cuts TP to HKD39

TIGERMED Plans to Spend Up to RMB1B to Repurchase A Shares